UNCY

Unicycive Therapeutics, Inc.
CAPPED RATING

Unicycive Therapeutics, Inc. (UNCY) is rated C+ (2.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (A+); its weakest is Momentum (D).

Quantitative Factor Evaluation • Updated

Overall Rating
2.8 / 5.0
C+
Value
B+
Factor Score 3.7 / 5.0
Growth
A+
Factor Score 5.0 / 5.0
Profitability
D
Factor Score 1.4 / 5.0
Momentum
D
Factor Score 1.4 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 2.4
EV / EBITDA -1.2
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -36.3%
Price Return 12M -30.9%
Catalyst Signal 0.00
Market Cap $97.2M
TTM Revenue N/A
Price / Sales N/A
ROE -101.1%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-15 B+ (3.7) A+ (5.0) D (1.4) D (1.4) C+ (2.6) C+ (2.8)
2026-11-08 B+ (3.7) A+ (5.0) D (1.4) D+ (1.7) C+ (2.6) B- (2.9)
2026-11-01 B+ (3.8) A+ (5.0) D+ (1.5) D+ (1.8) C+ (2.7) B- (3.0)
2026-10-25 B+ (3.7) A+ (5.0) D (1.5) D+ (1.8) C+ (2.6) B- (2.9)
2026-10-18 B+ (3.7) A+ (5.0) D (1.5) D+ (1.6) C+ (2.6) B- (2.9)
Page 1 of 3